Alessia Verduri1, Roxanna Short2, Ben Carter3, Philip Braude4, Arturo Vilches-Moraga5, Terence J Quinn6, Jemima Collins7, Jane Lumsden6, Kathryn McCarthy4, Louis Evans8, Phyo K Myint9, Jonathan Hewitt7. 1. Respiratory Unit, Hospital Policlinico Modena, University of Modena and Reggio Emilia, Modena, Italy. 2. Forensic and Neurodevelopmental Sciences, King's College London, London, UK. 3. Department of Biostatistics and Health Informatics, King's College London, London, UK. 4. Department of Surgery and Care of the Elderly, Southmead Hospital, North Bristol NHS Trust, Bristol, UK. 5. Ageing and Complex Medicine Department, Salford Royal NHS Trust, Manchester, UK. 6. Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK. 7. Cardiff and Vale UHB, Heath Park, Cardiff, UK. 8. Ysbyty Gwynedd Hospital, Betsi Cadwaladr University Health Board, Bangor, UK. 9. Institute of Applied Health Science, University of Aberdeen, Aberdeen, UK.
Abstract
BACKGROUND: Effective shielding measures and virus mutations have progressively modified the disease between the waves, likewise healthcare systems have adapted to the outbreak. Our aim was to compare clinical outcomes for older people with COVID-19 in Wave 1 (W1) and Wave 2 (W2). METHODS: All data, including the Clinical Frailty Scale (CFS), were collected for COVID-19 consecutive patients, aged ≥65, from 13 hospitals, in W1 (February-June 2020) and W2 (October 2020-March 2021). The primary outcome was mortality (time to mortality and 28-day mortality). Data were analysed with multilevel Cox proportional hazards, linear and logistic regression models, adjusted for wave baseline demographic and clinical characteristics. RESULTS: Data from 611 people admitted in W2 were added to and compared with data collected during W1 (N = 1340). Patients admitted in W2 were of similar age, median (interquartile range), W2 = 79 (73-84); W1 = 80 (74-86); had a greater proportion of men (59.4% vs. 53.0%); had lower 28-day mortality (29.1% vs. 40.0%), compared to W1. For combined W1-W2 sample, W2 was independently associated with improved survival: time-to-mortality adjusted hazard ratio (aHR) = 0.78 [95% confidence interval (CI) 0.65-0.93], 28-day mortality adjusted odds ratio = 0.80 (95% CI 0.62-1.03). W2 was associated with increased length of hospital stay aHR = 0.69 (95% CI 0.59-0.81). Patients in W2 were less frail, CFS [adjusted mean difference (aMD) = -0.50, 95% CI -0.81, -0.18], as well as presented with lower C-reactive protein (aMD = -22.52, 95% CI -32.00, -13.04). CONCLUSIONS: COVID-19 older adults in W2 were less likely to die than during W1. Patients presented to hospital during W2 were less frail and with lower disease severity and less likely to have renal decline.
BACKGROUND: Effective shielding measures and virus mutations have progressively modified the disease between the waves, likewise healthcare systems have adapted to the outbreak. Our aim was to compare clinical outcomes for older people with COVID-19 in Wave 1 (W1) and Wave 2 (W2). METHODS: All data, including the Clinical Frailty Scale (CFS), were collected for COVID-19 consecutive patients, aged ≥65, from 13 hospitals, in W1 (February-June 2020) and W2 (October 2020-March 2021). The primary outcome was mortality (time to mortality and 28-day mortality). Data were analysed with multilevel Cox proportional hazards, linear and logistic regression models, adjusted for wave baseline demographic and clinical characteristics. RESULTS: Data from 611 people admitted in W2 were added to and compared with data collected during W1 (N = 1340). Patients admitted in W2 were of similar age, median (interquartile range), W2 = 79 (73-84); W1 = 80 (74-86); had a greater proportion of men (59.4% vs. 53.0%); had lower 28-day mortality (29.1% vs. 40.0%), compared to W1. For combined W1-W2 sample, W2 was independently associated with improved survival: time-to-mortality adjusted hazard ratio (aHR) = 0.78 [95% confidence interval (CI) 0.65-0.93], 28-day mortality adjusted odds ratio = 0.80 (95% CI 0.62-1.03). W2 was associated with increased length of hospital stay aHR = 0.69 (95% CI 0.59-0.81). Patients in W2 were less frail, CFS [adjusted mean difference (aMD) = -0.50, 95% CI -0.81, -0.18], as well as presented with lower C-reactive protein (aMD = -22.52, 95% CI -32.00, -13.04). CONCLUSIONS: COVID-19 older adults in W2 were less likely to die than during W1. Patients presented to hospital during W2 were less frail and with lower disease severity and less likely to have renal decline.
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Lancet Date: 2007-10-20 Impact factor: 79.321
Authors: Jonathan Hewitt; Ben Carter; Arturo Vilches-Moraga; Terence J Quinn; Philip Braude; Alessia Verduri; Lyndsay Pearce; Michael Stechman; Roxanna Short; Angeline Price; Jemima T Collins; Eilidh Bruce; Alice Einarsson; Frances Rickard; Emma Mitchell; Mark Holloway; James Hesford; Fenella Barlow-Pay; Enrico Clini; Phyo K Myint; Susan J Moug; Kathryn McCarthy Journal: Lancet Public Health Date: 2020-06-30
Authors: Eilidh Bruce; Ben Carter; Terence J Quinn; Alessia Verduri; Oliver Pearson; Arturo Vilches-Moraga; Angeline Price; Aine McGovern; Louis Evans; Kathryn McCarthy; Jonathan Hewitt; Susan Moug; Phyo K Myint Journal: Eur J Public Health Date: 2022-02-01 Impact factor: 3.367
Authors: Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray Journal: N Engl J Med Date: 2020-07-17 Impact factor: 91.245
Authors: Angeline Price; Fenella Barlow-Pay; Siobhan Duffy; Lyndsay Pearce; Arturo Vilches-Moraga; Susan Moug; Terry Quinn; Michael Stechman; Philip Braude; Emma Mitchell; Phyo Kyaw Myint; Alessia Verduri; Kathryn McCarthy; Ben Carter; Jonathan Hewitt Journal: BMJ Open Date: 2020-09-29 Impact factor: 2.692